Two Directors at Smith & Nephew bought 42,920 shares at between 16.290USD and 16.989USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery. Analyzing real-world data from over 22,000 patients in the Premier PINC AI™ Healthcare Database, the ana...
UFC® and Smith+Nephew announce multi-year extension of partnership Smith+Nephew to continue as UFC’s Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world’s premier mixed martial arts organization, have announced a multi-year extension of their landmark worldwide marketing partnership forged in 2024. Under the renewal, Smith+Nephew will continue as UFC’s Preferred Sports Medicine Technology Partner, a designation it received as UFC’s inaugural partner in that category, to activate its brand around some of UF...
16th October 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: Epwin Group (EPWN.L) has left AIM. What’s baking in the...
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural Terminology (CPT) code for procedures involving its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027. The new CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a single-stage, off-the-shelf solution for treating cartilage and oste...
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal,1 demonstrating the pressure injury prevention mechanism of action of ALLEVYN COMPLETE CARE Foam Dressing and its ability to absorb and dissipate friction and shear forces. Pressure injuries are localized damage to the skin or underlying tissue, result...
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty, now available in the United States. This innovative software offers image-based planning capabilities that enable surgeons to create a patient-specific plan for shoulder replacement procedures by usin...
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries throughout ...
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, ...
Two Directors at ConvaTec Group bought 71,263 shares at between 234p and 235p. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.